tiprankstipranks
Blurbs

Analysts Are Bullish on These Healthcare Stocks: Brookdale Senior Living (BKD), Cybin (CYBN)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Brookdale Senior Living (BKDResearch Report), Cybin (CYBNResearch Report) and IVERIC bio (ISEEResearch Report) with bullish sentiments.

Brookdale Senior Living (BKD)

Barclays analyst Steven Valiquette maintained a Buy rating on Brookdale Senior Living on February 11 and set a price target of $9.00. The company’s shares closed last Friday at $5.48.

According to TipRanks.com, Valiquette is a 2-star analyst with an average return of 0.4% and a 54.8% success rate. Valiquette covers the Healthcare sector, focusing on stocks such as Bright Health Group, AmerisourceBergen, and Tenet Healthcare.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Brookdale Senior Living with a $8.40 average price target.

See today’s best-performing stocks on TipRanks >>

Cybin (CYBN)

In a report released today, Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Cybin, with a price target of $10.00. The company’s shares closed last Friday at $1.06, close to its 52-week low of $0.82.

According to TipRanks.com, Trucchio has 0 stars on 0-5 stars ranking scale with an average return of -17.8% and a 29.2% success rate. Trucchio covers the Healthcare sector, focusing on stocks such as Freeline Therapeutics Holdings, Milestone Pharmaceuticals, and Arrowhead Pharmaceuticals.

Cybin has an analyst consensus of Moderate Buy, with a price target consensus of $8.24.

IVERIC bio (ISEE)

H.C. Wainwright analyst Matthew Caufield reiterated a Buy rating on IVERIC bio today and set a price target of $26.00. The company’s shares closed last Friday at $15.38.

Caufield has an average return of 33.7% when recommending IVERIC bio.

According to TipRanks.com, Caufield is ranked #4425 out of 7791 analysts.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for IVERIC bio with a $25.33 average price target, implying a 59.6% upside from current levels. In a report issued on February 7, Morgan Stanley also initiated coverage with a Buy rating on the stock with a $25.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on BKD:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos
---

Latest News Feed